Browse the evidence

Transient reductions in fasting glucose were observed in participants with T2D, but these were not sustained and not significantly different from placebo at day 29.

While LY3537021 may reduce fasting glucose, the effects may not be long-lasting.

Co-stimulation of GLP-1 with other receptors like GIP and glucagon may provide additional therapeutic benefits.

Practitioners should consider combination therapies involving GLP-1 for enhanced weight loss effects.

Metformin was widely found to be weight-neutral with minimal effects on muscle mass.

Practitioners can consider Metformin as a weight-neutral option with minimal impact on muscle mass.

GLP-1 RA initiation was associated with a reduced incidence of all-cause mortality post RYGB (1.2% vs. 3.9%) with a hazard ratio of 0.497.

Practitioners may consider GLP-1 RAs to potentially improve survival rates in patients post RYGB.

Recent developments in bariatric medicine include novel anti-obesity drugs targeting appetite regulation and energy expenditure.

Practitioners should stay informed about new pharmacological options for obesity management.

The blood pressure-lowering effects of GLP-1 RAs are often independent of weight loss or glucose control.

GLP-1 RAs may be beneficial for hypertension management even in patients not focused on weight loss or glucose control.

Emerging translational applications include diagnostic and prognostic adipokine signatures and therapeutic impacts of GLP-1 receptor agonists.

These applications could enhance clinical practice in managing HFpEF.

Evidence suggests a reduced incidence of several gastrointestinal cancers with GLP-1 receptor agonist use.

GLP-1 receptor agonists may be considered for patients at risk of gastrointestinal cancers.

The development of oral formulations such as oral Semaglutide is expected to provide convenience for patients and enhance their willingness to receive treatment.

Practitioners should consider the potential of oral Semaglutide to improve patient adherence to obesity treatment.

GLP-1 receptor agonists have good safety and tolerability compared to traditional hypoglycemic drugs.

Practitioners can consider GLP-1 receptor agonists as a safer alternative for diabetes treatment.

Metformin seems to provide positive cardiovascular effects.

Practitioners may consider Metformin as a beneficial option for improving cardiovascular health in T2DM patients.

The SGLT2-inhibitor Empagliflozin reduces cardiovascular mortality, total mortality and hospitalization by heart failure.

Empagliflozin may be recommended for T2DM patients to reduce risks of cardiovascular mortality and hospitalization.

Insulin seems to be cardiovascular neutral, as well as the DPP4-inhibitors Saxagliptin, Sitagliptin and Alogliptin.

Insulin and certain DPP4-inhibitors may be considered safe options regarding cardiovascular health in T2DM patients.

Obesity prevalence has been increasing despite the regulation of body weight by a biological feedback control system.

Understanding the biological regulation of body weight can inform strategies for addressing obesity.

Neither Ins-30 nor genotype pattern modified the effect of diet on 12-month weight loss.

Individual factors like insulin secretion and genotype may not need to be considered when choosing between these diets for weight loss.

Obesity is influenced by biological, genetic, behavioural, and environmental factors.

Practitioners should consider multiple factors when addressing obesity.

GLP-1 receptor agonists (GLP-1RAs) have adverse events associated with their increased use.

Practitioners should be aware of the potential adverse events when prescribing GLP-1RAs.

GLP-1RAs users demonstrated significantly reduced risks of poor functional outcomes (odds ratio 0.37, 95% CI 0.21-0.66).

Using GLP-1 receptor agonists may enhance functional recovery in patients post-treatment.

GLP-1RAs users had significantly reduced risks of new subarachnoid hemorrhage (odds ratio 0.39, 95% CI 0.27-0.56).

GLP-1 receptor agonists may lower the risk of subarachnoid hemorrhage in treated patients.

Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.

Practitioners should adopt a long-term management strategy for obesity treatment.

NN501 causes weight loss without causing obvious aversive responses.

NN501 may provide a weight loss option without the side effects commonly associated with other treatments.

GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of corticosteroid use in patients with inflammatory bowel disease (IBD) compared to non-GLP-1 users.

Clinicians can consider GLP-1RAs for weight management in IBD patients without concern for increased corticosteroid use.

Reoperation odds among ACDF/GLP-1RA patients were significantly reduced at 12 months (4% vs. 6%; OR=0.689) and 24 months postoperatively (5% vs. 7%; OR=0.692).

GLP-1RAs may help reduce the need for reoperation in ACDF patients.

GLP-1RA use was associated with significantly reduced odds of pseudarthrosis by more than 20% and reoperation by more than 30% at 24 months following ACDF.

GLP-1RAs may significantly improve postoperative outcomes in ACDF patients.